会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • Funtionalised metallocenes as anticancer drugs
    • 功能金属茂作为抗癌药物
    • US20060106005A1
    • 2006-05-18
    • US10520477
    • 2003-07-04
    • Patrick McGowanRichard Knox
    • Patrick McGowanRichard Knox
    • A61K31/555C07F17/00
    • C07F17/00
    • The invention provides metallocene compounds of formula 1 for use as medicaments in the treatment of cancer. wherein R1, R2, R3 and R4 represent a combination of H, alkyl, aryl or trimethylsilyl; L represents side chain substituents, at least one of which contains a group which enables the compound to become water-solubilised; X is halo, alkoxy, acetate or H2O; Y is a counter-ion; M is a metal; and n=1 or 2. The invention also provides novel compounds of the formula 1 wherein at least one of the groups L comprises a quaternary tetraalkylammonium group. The compounds have been shown to have significantly greater activity in the treatment of cancer than the compounds known from the prior art.
    • 本发明提供式1的金属茂化合物,用作治疗癌症的药物。 其中R 1,R 2,R 3和R 4代表H,烷基,芳基或 三甲基甲硅烷基 L表示侧链取代基,其中至少一个含有使化合物变得水溶性的基团; X是卤素,烷氧基,乙酸酯或H 2 O; Y是抗衡离子; M是金属; 并且n = 1或2.本发明还提供式1的新化合物,其中基团L中的至少一个包含季铵四烷基铵基团。 已经表明,化合物在治疗癌症方面具有比现有技术已知的化合物显着更大的活性。
    • 7. 发明授权
    • Bacterial nitroreductase gene-prodrug system
    • 细菌硝基还原酶基因前体药物系统
    • US5958682A
    • 1999-09-28
    • US640808
    • 1996-07-01
    • Thomas ConnorsRichard KnoxRoger Sherwood
    • Thomas ConnorsRichard KnoxRoger Sherwood
    • C12N15/00A61K31/265A61K31/27A61K31/40A61K35/76A61K38/00A61K38/44A61K45/00A61K48/00A61P35/00A61P43/00C07H21/04C07K14/195C12N9/02C12N15/53C12N5/00
    • C12N9/0036A61K38/44A01K2217/05A61K48/00
    • A system is disclosed which comprises: (i) a viral vector comprising a nucleotide sequence encoding a nitroreductase, which nitroreductase is capable of converting a prodrug into a cytotoxic drug; and (ii) a prodrug capable of being converted into a cytotoxic drug by the nitroreductase encoded by the vector. The disclosed invention also includes methods for killing cancerous and/or non-cancerous cells using the system described above. Included in the invention are methods for killing cells in vitro by introducing a vector encoding a nitroreductase into the cells, and then by providing a prodrug to the cells growing in vitro. Also included are methods in which cancerous and/or non-cancerous cells are killed in vivo in an animal or human by administering the vector and prodrug directly to cells of the animal or human. The invention further includes methods in which cancerous and/or non-cancerous cells are killed in vivo in an animal or human, by introducing a viral vector encoding a nitroreductase into animal or human cells growing in vitro so that the nitroreductase is produced in the cells, administering the cells to an animal or human subject, and then administering a prodrug to the animal or human, where it is converted into a cytotoxic agent in nitroreductase-containing cells of the animal or human.
    • PCT No.PCT / GB94 / 02423 Sec。 371日期:1996年7月1日 102(e)日期1996年7月1日PCT 1994年11月4日PCT PCT。 WO95 / 12678 PCT出版物 日期1995年5月11日公开了一种系统,其包括:(i)包含编码硝基还原酶的核苷酸序列的病毒载体,所述硝基还原酶能够将前药转化为细胞毒性药物; 和(ii)能够通过载体编码的硝基还原酶转化成细胞毒性药物的前药。 所公开的发明还包括使用上述系统杀死癌和/或非癌细胞的方法。 本发明包括通过将编码硝基还原酶的载体引入细胞,然后通过向体外生长的细胞提供前体来在体外杀死细胞的方法。 还包括通过将该载体和前药直接施用于动物或人的细胞,在动物或人体内将癌和/或非癌细胞体内杀死的方法。 本发明还包括通过将编码硝基还原酶的病毒载体引入体外生长的动物或人类细胞中,使动物或人体内杀死癌细胞和/或非癌细胞的方法,使得在细胞中产生硝基还原酶 给动物或人类受试者施用细胞,然后向动物或人施用前体药物,在动物或人类的硝酸还原酶细胞中转化成细胞毒性剂。